Analysts expect Insulet to report Q2 2026 revenue of $787.4 million and earnings of $1.44 per share, with the stock currently trading at $165.35 against an average analyst target of $235.54. The central story for this report is the commercial momentum of the Omnipod 5 system within the Type 2 diabetes market and its integration with next-generation continuous glucose monitoring sensors.
Investors are particularly interested in whether Insulet can maintain its 21-23% revenue growth guidance despite emerging legal challenges and intensifying competition from Medtronic and Tandem. Recent performance was bolstered by a significant Q1 beat, which led management to raise full-year 2026 sales forecasts to a range of $3.28 billion to $3.33 billion.